Four months after new rules adopted by the U.S. Department of the Treasury foiled Pfizer Inc.’s plans to acquire Allergan plc in a $160 billion tax inversion deal, the New York-based pharmaceutical giant has moved on to pick up a cancer drug maker with four Am Law 100 firms in tow.
On Monday, Pfizer announced that it has agreed to acquire San Francisco-based Medivation—manufacturer of the prostate cancer treatment drug Xtandi—in an all-cash deal valued at $14 billion, including debt. Ropes & Gray, a longtime legal adviser to Pfizer, has once again snagged the lead role for Pfizer through M&A partner Christopher Comeau in New York.
